Comparative Efficacy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone and Versus Belamaf, Pomalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Previously Treated With 1–3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison